GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Tenax Therapeutics Inc (FRA:YBO0) » Definitions » Loans Receivable

Tenax Therapeutics (FRA:YBO0) Loans Receivable : €0.00 Mil (As of Mar. 2024)


View and export this data going back to 2008. Start your Free Trial

What is Tenax Therapeutics Loans Receivable?

Tenax Therapeutics's Loans Receivable for the quarter that ended in Mar. 2024 was €0.00 Mil.


Tenax Therapeutics Loans Receivable Historical Data

The historical data trend for Tenax Therapeutics's Loans Receivable can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Tenax Therapeutics Loans Receivable Chart

Tenax Therapeutics Annual Data
Trend Apr14 Apr15 Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23
Loans Receivable
Get a 7-Day Free Trial Premium Member Only Premium Member Only - - - - -

Tenax Therapeutics Quarterly Data
Jun19 Sep19 Dec19 Mar20 Jun20 Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24
Loans Receivable Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only - - - - -

Tenax Therapeutics Loans Receivable Calculation

Loans Receivable are the funds that a company has lent but have not yet been repaid.


Tenax Therapeutics Loans Receivable Related Terms

Thank you for viewing the detailed overview of Tenax Therapeutics's Loans Receivable provided by GuruFocus.com. Please click on the following links to see related term pages.


Tenax Therapeutics (FRA:YBO0) Business Description

Traded in Other Exchanges
Address
101 Glen Lennox Drive, Suite 300, Chapel Hill, NC, USA, 27517
Tenax Therapeutics Inc is a specialty pharmaceutical company focused on identifying, developing, and commercializing products that address cardiovascular and pulmonary diseases with high unmet medical needs. The company owns North American rights to develop and commercialize levosimendan and has released topline data regarding the Phase 2 clinical trial for the use of levosimendan in the treatment of Pulmonary Hypertension associated with Heart Failure and preserved Ejection Fraction.

Tenax Therapeutics (FRA:YBO0) Headlines

No Headlines